Tenax Therapeutics, Inc.: Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
Tenax Therapeutics (Nasdaq: TENX) said Phase 3 LEVEL trial data for TNX-103 (oral levosimendan) in PH-HFpEF will be presented at the ESC Congress 2026 (Aug 28-31) via a late-breaking session on Aug 29. The company expects topline results in August after database lock and statistical analysis; enrollment of 230+ patients was completed in March 2026.
How this was made
The 30-second read
Why it matters
The company’s late-breaking ESC presentation plan and August topline expectation create a clear pre-data catalyst window, potentially increasing trading activity and volatility as the market re-prices Phase 3 outcome probabilities.
Market read
This is a time-specific catalyst for TENX ahead of topline LEVEL results, but it contains no efficacy/safety numbers yet.
What to watch
Key details like interim readouts, safety signals, and endpoint magnitude are not provided; the market may wait for actual topline rather than the conference slot.
Background
Tenax’s registrational Phase 3 LEVEL trial (TNX-103 oral levosimendan) in PH-HFpEF completed enrollment (>230 patients) and is powered for a 25-meter 6MWD change.
Ticker impact
Tenax says Phase 3 LEVEL trial results will be presented as late-breaking data at ESC Congress 2026 and expects topline in August.
Moderate near-term support for the stock into August as traders price in higher odds of favorable LEVEL topline.
The article provides a concrete, time-bound catalyst (ESC late-breaking session) plus a revised/confirmed reporting window (August 2026), but it does not disclose the actual results.
Market effects
Adds incremental momentum for cardiopulmonary/pharma trial narratives, but without disclosed efficacy/safety outcomes it’s not a sector reset.
Primarily US small/mid-cap biotech sentiment with spillover to Europe conference attention.
Limited global impact absent disclosed topline efficacy/safety; mainly affects expectations for levosimendan in PH-HFpEF.
Counterpoint
Late-breaking presentation does not guarantee positive topline; traders may be over-weighting the visibility while underestimating risk of neutral/negative results.
Key entities
- companyTenax Therapeutics, Inc.
Nasdaq-listed developer of oral levosimendan (TNX-103) for PH-HFpEF; advancing Phase 3 LEVEL toward topline in August 2026.
- clinical_trialLEVEL (NCT05983250)
Phase 3 trial evaluating TNX-103 in pulmonary hypertension due to heart failure with preserved ejection fraction; enrollment completed March 2026.
- conferenceESC Congress 2026
European Society of Cardiology Congress in Munich (Aug 28-31, 2026) where LEVEL data will be presented in a late-breaking session.
